Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.

Olayanju O, Esmail A, Limberis J, Dheda K.

Eur Respir J. 2020 Jan 16;55(1). pii: 1901181. doi: 10.1183/13993003.01181-2019. Print 2020 Jan.

PMID:
31619478
2.

Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen.

Olayanju O, Esmail A, Limberis J, Gina P, Dheda K.

Int J Infect Dis. 2019 Aug;85:74-79. doi: 10.1016/j.ijid.2019.04.028. Epub 2019 May 14.

3.

Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.

Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, Fadul M, Warren R, Dheda K.

Eur Respir J. 2018 May 30;51(5). pii: 1800544. doi: 10.1183/13993003.00544-2018. Print 2018 May.

4.

Salivary immunoglobulin classes in Nigerian smokers with periodontitis.

Olayanju OA, Rahamon SK, Joseph IO, Arinola OG.

World J Biol Chem. 2012 Oct 26;3(10):180-3. doi: 10.4331/wjbc.v3.i10.180.

5.

Salivary immunoglobulin classes in Nigerians with periodontitis.

Olayanju OA, Rahamon SK, Joseph IO, Arinola OG.

J Contemp Dent Pract. 2012 Mar 1;13(2):163-6.

PMID:
22665741

Supplemental Content

Loading ...
Support Center